News
Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback